12.02
price down icon0.66%   -0.08
after-market アフターアワーズ: 11.80 -0.22 -1.83%
loading
前日終値:
$12.10
開ける:
$12.11
24時間の取引高:
1.71M
Relative Volume:
1.05
時価総額:
$1.24B
収益:
-
当期純損益:
$-135.21M
株価収益率:
-8.3991
EPS:
-1.4311
ネットキャッシュフロー:
$-114.35M
1週間 パフォーマンス:
+15.36%
1か月 パフォーマンス:
+26.13%
6か月 パフォーマンス:
-0.74%
1年 パフォーマンス:
+5.07%
1日の値動き範囲:
Value
$11.92
$12.57
1週間の範囲:
Value
$10.37
$12.57
52週間の値動き範囲:
Value
$7.23
$14.93

Oric Pharmaceuticals Inc Stock (ORIC) Company Profile

Name
名前
Oric Pharmaceuticals Inc
Name
セクター
Healthcare (1074)
Name
電話
(650) 388-5600
Name
住所
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Name
職員
104
Name
Twitter
Name
次回の収益日
2026-08-11
Name
最新のSEC提出書
Name
ORIC's Discussions on Twitter

Compare ORIC vs VRTX, REGN, ARGX, RVMD, ALNY

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
ORIC icon
ORIC
Oric Pharmaceuticals Inc
12.02 1.25B 0 -135.21M -114.35M -1.4311
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
479.00 121.16B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
667.17 68.78B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
888.82 57.44B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
188.07 40.23B 742.00K -1.37B -1.07B -7.0731
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
278.40 36.28B 4.29B 577.22M 641.34M 4.2086

Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-06-12 再開されました Stifel Buy
2026-05-15 アップグレード Goldman Neutral → Buy
2026-01-07 開始されました Piper Sandler Overweight
2025-11-20 開始されました Evercore ISI Outperform
2025-11-18 開始されました Wolfe Research Peer Perform
2025-09-04 再開されました Guggenheim Buy
2025-07-08 開始されました Ladenburg Thalmann Buy
2024-10-31 開始されました Wells Fargo Overweight
2024-09-06 開始されました Stifel Buy
2024-02-23 開始されました Cantor Fitzgerald Overweight
2023-09-22 開始されました Wedbush Outperform
2023-03-23 アップグレード H.C. Wainwright Neutral → Buy
2023-03-21 アップグレード Guggenheim Neutral → Buy
2023-03-16 アップグレード Oppenheimer Perform → Outperform
2022-07-18 再開されました Oppenheimer Perform
2022-04-04 アップグレード Citigroup Neutral → Buy
2022-03-25 ダウングレード H.C. Wainwright Buy → Neutral
2022-03-22 ダウングレード Citigroup Buy → Neutral
2022-03-22 ダウングレード Guggenheim Buy → Neutral
2022-03-22 ダウングレード Oppenheimer Outperform → Perform
2021-07-06 アップグレード Citigroup Neutral → Buy
2021-01-25 ダウングレード Citigroup Buy → Neutral
2020-08-13 開始されました Robert W. Baird Outperform
2020-08-06 アップグレード Citigroup Neutral → Buy
2020-08-03 開始されました H.C. Wainwright Buy
2020-05-19 開始されました Citigroup Neutral
2020-05-19 開始されました Guggenheim Buy
2020-05-19 開始されました JP Morgan Overweight
2020-05-19 開始されました Jefferies Buy
すべてを表示

Oric Pharmaceuticals Inc (ORIC) 最新ニュース

pulisher
12:36 PM

Oric Pharmaceuticals Inc (ORIC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

12:36 PM
pulisher
09:05 AM

Oric Pharmaceuticals Inc (ORIC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

09:05 AM
pulisher
06:38 AM

Orbimed Advisors LLC Reduces Stock Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat

06:38 AM
pulisher
04:36 AM

ORIC|Oric Pharmaceuticals Inc|Price:12.100|Chg%:+1.210 - TradingKey

04:36 AM
pulisher
03:31 AM

Oric Pharmaceuticals Inc (ORIC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

03:31 AM
pulisher
12:10 PM

TradingKey - TradingKey

12:10 PM
pulisher
Jul 26, 2026

Oric Pharmaceuticals Inc (ORIC) Institutional Confidence - TradingKey

Jul 26, 2026
pulisher
Jul 25, 2026

Oric Pharmaceuticals Inc (ORIC) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jul 25, 2026
pulisher
Jul 25, 2026

Oric Pharmaceuticals Inc (ORIC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jul 25, 2026
pulisher
Jul 25, 2026

Oric Pharmaceuticals (NASDAQ:ORIC) Upgraded at Wall Street Zen - MarketBeat

Jul 25, 2026
pulisher
Jul 24, 2026

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Jul 24, 2026
pulisher
Jul 24, 2026

Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 5.4%Time to Buy? - MarketBeat

Jul 24, 2026
pulisher
Jul 24, 2026

Siren L.L.C. Has $37.99 Million Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat

Jul 24, 2026
pulisher
Jul 24, 2026

Oric Pharmaceuticals (ORIC) Stock Analysis: A Biotech Gem With An 86% Upside Potential - DirectorsTalk Interviews

Jul 24, 2026
pulisher
Jul 22, 2026

ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits

Jul 22, 2026
pulisher
Jul 21, 2026

ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen Bull Case (NASDAQ:ORIC) - Seeking Alpha

Jul 21, 2026
pulisher
Jul 20, 2026

Oric Pharmaceuticals stock trades down to 10.69 as oricpharma promotes BTIG conference meeting - Traders Union

Jul 20, 2026
pulisher
Jul 20, 2026

Discipline and Rules-Based Execution in ORIC Response - Stock Traders Daily

Jul 20, 2026
pulisher
Jul 20, 2026

ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 - The Manila Times

Jul 20, 2026
pulisher
Jul 20, 2026

ORIC® Pharmaceuticals Announces Three Presentations at the - GlobeNewswire

Jul 20, 2026
pulisher
Jul 20, 2026

Oric Pharmaceuticals (ORIC) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat

Jul 20, 2026
pulisher
Jul 16, 2026

How ORIC’s Global Phase 3 Rinzimetostat Trial with Bayer’s NUBEQA Has Changed Its Investment Story (ORIC) - Sahm

Jul 16, 2026
pulisher
Jul 16, 2026

ORIC Launches Phase 3 Himalayas-1 Trial - t.co

Jul 16, 2026
pulisher
Jul 16, 2026

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Jul 16, 2026
pulisher
Jul 15, 2026

ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer - Sahm

Jul 15, 2026
pulisher
Jul 15, 2026

Oric Pharmaceuticals (ORIC) Launches Phase 3 Trial for Prostate Cancer Treatment - GuruFocus

Jul 15, 2026
pulisher
Jul 14, 2026

ORIC Pharmaceuticals initiates phase 3 prostate cancer trial - Investing.com

Jul 14, 2026
pulisher
Jul 14, 2026

ORIC Pharmaceuticals initiates phase 3 prostate cancer trial By Investing.com - Investing.com India

Jul 14, 2026
pulisher
Jul 14, 2026

Bayer Will Provide NUBEQA at No Cost for ORIC’s Global Trial - Stock Titan

Jul 14, 2026
pulisher
Jul 11, 2026

Y Intercept Hong Kong Ltd Sells 229,431 Shares of Oric Pharmaceuticals, Inc. $ORIC - MarketBeat

Jul 11, 2026
pulisher
Jul 08, 2026

Oric Pharmaceuticals director Heyman sells $3,600 in stock - Investing.com

Jul 08, 2026
pulisher
Jul 08, 2026

Form 4 Oric Pharmaceuticals Inc For: 8 July By Investing.com - Investing.com South Africa

Jul 08, 2026
pulisher
Jul 08, 2026

Oric Pharmaceuticals director Heyman sells $3,600 in stock By Investing.com - Investing.com India

Jul 08, 2026
pulisher
Jul 08, 2026

Oric Pharmaceuticals (ORIC) entity sells 300 shares under 10b5-1 plan - Stock Titan

Jul 08, 2026
pulisher
Jul 07, 2026

Price to sales forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView

Jul 07, 2026
pulisher
Jul 07, 2026

ORIC focuses on oncology pipeline as Oric Pharmaceuticals positions for long-term growth - Ad Hoc News

Jul 07, 2026
pulisher
Jul 07, 2026

Price to sales forward of Oric Pharmaceuticals, Inc. – DUS:4TZ - TradingView

Jul 07, 2026
pulisher
Jul 06, 2026

Form 144 Oric Pharmaceuticals For: 6 July By Investing.com - Investing.com Nigeria

Jul 06, 2026
pulisher
Jul 06, 2026

ORIC (NASDAQ) Form 144: Affiliate notifies sale of 7,000 Common shares via J.P. Morgan - Stock Titan

Jul 06, 2026
pulisher
Jul 06, 2026

[144] Oric Pharmaceuticals, Inc. SEC Filing - Stock Titan

Jul 06, 2026
pulisher
Jul 06, 2026

ORIC Pharmaceuticals Slips 2.49% as Stock Tests Key Support LevelsBreakout Stock Alerts - DonanımHaber

Jul 06, 2026
pulisher
Jul 03, 2026

Oric Pharmaceuticals stock extends rally with bullish signals after 22 percent weekly surge - Traders Union

Jul 03, 2026
pulisher
Jul 02, 2026

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 02, 2026
pulisher
Jul 02, 2026

ORIC awards new hires 44,400 stock options and 7,200 RSUs - Stock Titan

Jul 02, 2026
pulisher
Jul 02, 2026

ORIC Pharmaceuticals grants stock options and r... - Pluang

Jul 02, 2026
pulisher
Jun 29, 2026

Wedbush reiterates ORIC Pharmaceuticals (ORIC) outperform recommendation - MSN

Jun 29, 2026
pulisher
Jun 29, 2026

Enterprise value to EBITDA forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView

Jun 29, 2026
pulisher
Jun 28, 2026

Price to earnings forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Price to book forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Enterprise value to revenue forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Enterprise value to EBIT forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView

Jun 28, 2026

Oric Pharmaceuticals Inc (ORIC) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$91.09
price up icon 1.97%
$118.87
price up icon 1.02%
$34.72
price down icon 0.83%
$58.73
price down icon 0.17%
ONC ONC
$325.90
price up icon 0.00%
$278.40
price up icon 2.44%
大文字化:     |  ボリューム (24 時間):